Table 5 Characteristics and outcomes of patients enrolled to the QUAZAR study or the ALLG NBCR aged ≥55 years in CR or CRi after intensive chemotherapy#.
Characteristics | CC-486 (EXP) (N = 238) | CC-486 (PBO) (N = 234) | NBCR (no HCT) (N = 185) | NBCR (HCT) (N = 54) | P* |
|---|---|---|---|---|---|
Age, years, median (range) | 68 (55–86) | 68 (55–82) | 65 (55–77) | 59 (55–69) | <0.001 |
- Age ≥65 years, n (%) | 172 (72) | 166 (71) | 94 (51) | 10 (19) | <0.001 |
Male gender, n (%) | 118 (50) | 127 (54) | 103 (56) | 29 (54) | 0.9 |
Cytogenetic risk according to NCCN version 2.2011, n (%) | 0.04 | ||||
- Intermediate | 203 (85) | 203 (87) | 155/181 (86) | 39 (72) | |
- Adverse | 35 (15) | 31 (13) | 26/181 (14) | 15 (28) | |
De novo AML, n (%) | 213 (89) | 216 (92) | 174 (94) | 49 (91) | 0.4 |
Treatment response, n (%) | 1 | ||||
- CR | 187 (79) | 197 (84) | 155 (84) | 46 (85) | |
- CRi | 51 (21) | 37 (16) | 30 (16) | 8 (15) | |
Received consolidation, n (%) | 0.4 | ||||
- No | 52 (22) | 42 (18) | 21 (11) | 8 (15) | |
- 1 cycle | 110 (46) | 102 (44) | 130 (70) | 40 (74) | |
- ≥2 cycles | 76 (32) | 90 (39) | 34 (18) | 6 (11) | |
OS, months, median (95% CI) | 24.7 (18.7–30.5) | 14.8 (11.7–17.6) | 32.2 (23.3–48.1) | NR (42.3–NR) | 0.04 |
